Notably, the presence of TRMT11-GRIK2 in ductal type breast cancers and in liver cancers was associated with more favourable outcomes, in contrast to prostate cancers positive for this fusion gene where patients exhibit worse clinical outcomes [131], suggesting fusion genes may have different effects depending on the cancer. This evidence concerns the gene TRMT11 and cancer.